European Journal of Clinical Pharmacy
Print ISSN: 2385-409X **Online ISSN**: 3105-0409
Website: https://farmclin.com/

Original Research Article

Platelet Aggregation in Coronary Heart Disease and the Efficacy of Antiplatelet Therapy: A Review

Article History:

Name of Author:
Khodjanova Sh.I.[1], Alavi A.L.[2], Abdullaev A.O.[3] and Kodirova Sh.A.[4]

Affiliation: *[1]PhD., Senior Lecturer, Tashkent Medical Academy*
[2]Doctor Of Medical Sciences, Academic, Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation Tashkent, Uzbekistan
[3]Candidate Of Medical Sciences, Head Of Biomedical Technology Center, Tashkent Medical Academy Tashkent, Uzbekistan
[4]Senior Lecturer, Tashkent Medical Academy
Corresponding Author:
Khodjanova Sh.I.

Received: 28-12-2025
Revised: *18*-01-2026
Accepted: 05-02-2026
Published: 20-02-2026

Abstract: Coronary heart disease (CHD) remains one of the leading causes of morbidity and mortality worldwide, with platelet aggregation playing a crucial role in its pathogenesis. Increased platelet activation leads to thrombus formation, which can result in acute coronary syndromes. Understanding the mechanisms of platelet aggregation and the efficacy of antiplatelet therapy is essential for optimizing treatment strategies. This review explores the pathophysiological basis of platelet aggregation in CHD, methods for assessing platelet function, and the clinical effectiveness of various antiplatelet agents, including aspirin, clopidogrel, ticagrelor, and prasugrel. Additionally, we discuss recent advancements in antiplatelet therapy and their potential impact on patient outcomes.

Keywords: Coronary heart disease, platelet aggregation, antiplatelet therapy, aspirin, clopidogrel, ticagrelor, prasugrel, thrombosis, cardiovascular risk.

INTRODUCTION

Coronary heart disease (CHD) remains the leading cause of cardiovascular morbidity and mortality worldwide. It is primarily caused by atherosclerosis, a progressive inflammatory condition characterized by lipid deposition and plaque formation within the coronary arteries[1.3.4]. One of the critical factors contributing to the progression of CHD is platelet aggregation, which plays a central role in thrombosis and acute coronary syndromes (ACS). Platelets, upon activation, adhere to the damaged endothelium, release prothrombotic factors, and aggregate to form a thrombus that can occlude coronary arteries, leading to myocardial infarction or unstable angina.

Understanding the mechanisms of platelet aggregation and the efficacy of antiplatelet therapy is crucial for optimizing treatment strategies in CHD patients. Antiplatelet agents, such as aspirin, P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel), and glycoprotein IIb/IIIa inhibitors, have significantly improved outcomes in patients at risk of thrombotic events. Despite their benefits, challenges such as interindividual variability in drug response, resistance to certain agents, and bleeding risks remain concerns in clinical practice.

This review aims to provide a comprehensive analysis of platelet aggregation in CHD, methods for assessing platelet function, and the effectiveness of different antiplatelet therapies. Additionally, we will explore

novel approaches to improving antiplatelet treatment efficacy and reducing adverse effects in CHD management.

Pathogenesis and Mechanisms of Platelet Aggregation in Coronary Heart Disease

Role of Platelets in Atherosclerosis and Thrombosis

Platelets play a crucial role in hemostasis, but their excessive activation contributes to the pathogenesis of coronary heart disease (CHD). Atherosclerosis, the underlying cause of CHD, is characterized by endothelial dysfunction, lipid accumulation, and chronic inflammation. When the integrity of the endothelium is compromised due to plaque rupture or erosion, subendothelial components such as collagen and von Willebrand factor (vWF) become exposed, triggering platelet adhesion and activation[3.6].

Upon activation, platelets undergo morphological changes, release prothrombotic granules, and synthesize thromboxane A_2 (TXA_2), a potent vasoconstrictor and platelet aggregator. Additionally, activated platelets express glycoprotein IIb/IIIa (GP IIb/IIIa) receptors, facilitating fibrinogen-mediated platelet-platelet interactions and thrombus formation. This process can lead to partial or complete coronary artery occlusion, resulting in acute coronary syndromes (ACS), including unstable angina and myocardial infarction.

Pathophysiological Mechanisms of Platelet Activation

Several key mechanisms contribute to platelet activation in CHD:

1. **Endothelial Dysfunction** – Reduced nitric oxide (NO) and prostacyclin production lead to increased platelet adhesion and aggregation.
2. **Inflammation** – Pro-inflammatory cytokines (e.g., interleukin-6, tumor necrosis factor-alpha) enhance platelet reactivity and promote thrombosis.
3. **Oxidative Stress** – Reactive oxygen species (ROS) damage endothelial cells, reducing their antithrombotic properties and amplifying platelet activation.
4. **Lipid Abnormalities** – Oxidized low-density lipoproteins (oxLDL) stimulate platelet activation via scavenger receptors, contributing to plaque instability.
5. **Hypercoagulability** – Increased thrombin generation enhances platelet aggregation and fibrin clot formation.

Molecular Pathways Involved in Platelet Aggregation

Platelet aggregation is primarily mediated by three signaling pathways:

- **Thromboxane A_2 (TXA_2) Pathway** – TXA_2 is synthesized from arachidonic acid via cyclooxygenase-1 (COX-1) and acts on TP receptors to promote platelet activation. Aspirin exerts its antiplatelet effect by irreversibly inhibiting COX-1.
- **Adenosine Diphosphate (ADP) Pathway** – ADP binds to P2Y12 receptors on platelets, amplifying aggregation. P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) block this pathway, reducing thrombus formation.
- **Glycoprotein IIb/IIIa Pathway** – GP IIb/IIIa receptors facilitate fibrinogen cross-linking between platelets, forming a stable thrombus. GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) target this pathway in high-risk patients.

Clinical Implications

Understanding these pathophysiological mechanisms has led to the development of targeted antiplatelet therapies aimed at reducing thrombotic events while minimizing bleeding risks. However, variability in platelet response, genetic polymorphisms, and drug resistance remain significant challenges in optimizing treatment outcomes.

Assessment of Platelet Aggregation in Coronary Heart Disease

Accurate assessment of platelet aggregation is crucial for evaluating thrombotic risk in coronary heart disease (CHD) patients and optimizing antiplatelet therapy. Various laboratory methods have been developed to measure platelet function, ranging from traditional aggregation assays to advanced point-of-care testing. These techniques help identify patients with high platelet reactivity (HPR) or resistance to antiplatelet drugs, allowing for personalized treatment approaches[5.6.9].

1. Light Transmission Aggregometry (LTA)

LTA is the gold standard for assessing platelet aggregation and function. It measures changes in light transmission through platelet-rich plasma (PRP) in response to agonists such as adenosine diphosphate (ADP), arachidonic acid, thrombin receptor-activating peptide (TRAP), and collagen.

- **Advantages:** High sensitivity, well-established method.
- **Limitations:** Requires specialized equipment, time-consuming, and sample preparation is complex.

2. VerifyNow® System

The VerifyNow® system is a rapid, point-of-care assay designed to assess platelet function based on whole blood impedance. It evaluates responses to aspirin, P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel), and GP IIb/IIIa inhibitors.

- **Advantages:** Quick results, minimal sample preparation, suitable for routine clinical use.

- **Limitations:** Less sensitive than LTA, unable to assess all platelet activation pathways.

3. Platelet Function Analyzer (PFA-100/200)

The PFA-100/200 system assesses platelet function under shear stress by measuring closure time in response to collagen and epinephrine or ADP.

- **Advantages:** Simulates physiological conditions, rapid and automated.
- **Limitations:** Influenced by hematocrit and von Willebrand factor levels, limited specificity for P2Y12 inhibitors.

4. Flow Cytometry

Flow cytometry allows for the detection of platelet activation markers, such as P-selectin (CD62P) and activated GP IIb/IIIa, using fluorescently labeled antibodies.

- **Advantages:** High specificity and sensitivity, can assess multiple platelet activation pathways.
- **Limitations:** Requires expertise, expensive, and time-consuming.

5. Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM)

These viscoelastic tests provide a global assessment of hemostasis, including platelet function, fibrin clot formation, and fibrinolysis.

- **Advantages:** Useful in perioperative and critical care settings, assesses overall clot stability.
- **Limitations:** Less specific for platelet aggregation, requires specialized equipment.

6. Genetic Testing for Antiplatelet Response

Genetic polymorphisms, particularly CYP2C19 variations, influence clopidogrel metabolism and response. Testing for CYP2C19 loss-of-function alleles can help identify patients who may benefit from alternative P2Y12 inhibitors such as ticagrelor or prasugrel.

- **Advantages:** Identifies genetic resistance to clopidogrel, personalized treatment potential.
- **Limitations:** Not widely available, costly, and clinical utility remains debated.

Assessing platelet function is essential for optimizing antiplatelet therapy in CHD patients. Individuals with high platelet reactivity may require alternative or intensified therapy to reduce thrombotic risk, whereas those with excessive platelet inhibition may be at increased risk of bleeding. Personalized approaches based on platelet function testing can improve treatment outcomes and minimize adverse events[11.13].

Efficacy of Antiplatelet Therapy in Coronary Heart Disease

Antiplatelet therapy is a cornerstone in the management of coronary heart disease (CHD), particularly for preventing thrombotic complications such as myocardial infarction and stent thrombosis. Various antiplatelet agents target different pathways of platelet activation, improving clinical outcomes. However, individual responses to therapy vary, necessitating a tailored approach to treatment.

1. Aspirin and Its Effectiveness

Aspirin is a widely used antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A_2 (TXA_2) production and preventing platelet aggregation.

- **Clinical efficacy:** Studies have demonstrated that aspirin reduces the risk of major adverse cardiovascular events (MACE) by approximately 25% in CHD patients.
- **Limitations:** Aspirin resistance occurs in 10-30% of patients, leading to reduced effectiveness. Additionally, long-term use increases the risk of gastrointestinal bleeding.

2. P2Y12 Inhibitors: Clopidogrel, Prasugrel, and Ticagrelor

These drugs block the P2Y12 receptor, preventing ADP-induced platelet activation.

- **Clopidogrel:** A second-line antiplatelet drug used in dual antiplatelet therapy (DAPT) with aspirin.
    - **Effectiveness:** Reduces recurrent ischemic events, particularly in acute coronary syndrome (ACS) and post-percutaneous coronary intervention (PCI) patients.
    - **Limitations:** Up to 30% of patients exhibit high platelet reactivity due to genetic polymorphisms (CYP2C19 variants), reducing drug efficacy.
- **Prasugrel:** A more potent and consistent P2Y12 inhibitor than clopidogrel.
    - **Effectiveness:** Demonstrated superior efficacy in the TRITON-TIMI 38 trial, reducing ischemic events in ACS patients undergoing PCI.
    - **Limitations:** Higher risk of bleeding, contraindicated in patients with prior stroke or transient ischemic attack (TIA).
- **Ticagrelor:** A reversible P2Y12 inhibitor with faster onset and greater potency than clopidogrel.
    - **Effectiveness:** The PLATO trial showed a significant reduction in cardiovascular mortality compared to clopidogrel.

- **Limitations:** May cause dyspnea and an increased risk of bleeding.

3. Glycoprotein IIb/IIIa Inhibitors

These agents (abciximab, eptifibatide, tirofiban) block fibrinogen-mediated platelet aggregation, preventing thrombus formation.

- **Effectiveness:** Used in high-risk PCI patients and ACS to reduce immediate thrombotic complications.
- **Limitations:** High bleeding risk limits long-term use.

4. Emerging Antiplatelet Agents

- **Vorapaxar:** A PAR-1 antagonist that inhibits thrombin-mediated platelet activation.
  - **Effectiveness:** Shown to reduce thrombotic events in secondary prevention of CHD.
  - **Limitations:** High risk of intracranial hemorrhage.
- **Cangrelor:** An intravenous P2Y12 inhibitor with rapid onset and offset.
  - **Effectiveness:** Beneficial for patients undergoing urgent PCI.
  - **Limitations:** Short duration of action requires transition to oral therapy.

5. Dual and Triple Antiplatelet Therapy

- **Dual Antiplatelet Therapy (DAPT):** Combination of aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) is the standard treatment for ACS and post-PCI patients.
- **Triple Therapy:** Involves DAPT with an oral anticoagulant (e.g., warfarin, DOACs) in patients with atrial fibrillation and CHD.
  - **Challenges:** Increased bleeding risk necessitates careful patient selection.

Clinical Implications

The choice of antiplatelet therapy depends on patient-specific factors such as genetic variability, bleeding risk, and comorbidities. Personalized approaches, including platelet function testing and genetic screening, may help optimize therapy and improve patient outcomes.

Table: Comparison of Common Antiplatelet Agents

Drug	Mechanism of Action	Indication	Bleeding Risk	Advantages	Disadvantages
Aspirin	COX-1 inhibitor, reduces TXA2	CHD, stroke prevention	Low to moderate	Low cost, well-studied	GI bleeding, aspirin resistance
Clopidogrel	P2Y12 receptor inhibitor	PCI, ACS, stroke prevention	Moderate	Once-daily dosing	CYP2C19 variability affects efficacy
Prasugrel	P2Y12 receptor inhibitor	ACS, PCI	High	More potent than clopidogrel	Increased bleeding risk, contraindicated in stroke patients
Ticagrelor	Reversible P2Y12 receptor inhibitor	ACS, PCI	High	Faster onset, more effective than clopidogrel	Dyspnea, BID dosing required
Vorapaxar	PAR-1 thrombin receptor inhibitor	Secondary MI prevention	High	Novel mechanism	Not for patients with prior stroke

Challenges in Antiplatelet Therapy

1. High Platelet Reactivity (HPR): Some CHD patients, particularly those with CYP2C19 polymorphisms, exhibit resistance to clopidogrel, increasing thrombotic risk.
2. Bleeding Complications: Potent antiplatelet drugs (prasugrel, ticagrelor, GP IIb/IIIa inhibitors) increase the risk of major bleeding, especially in elderly or anticoagulated patients.
3. Optimal Therapy Duration: Long-term DAPT reduces thrombotic events but increases bleeding risk, making duration optimization crucial.
4. Drug Interactions: Proton pump inhibitors (PPIs) and other medications may reduce antiplatelet drug efficacy.

Future Perspectives

1. Personalized Antiplatelet Therapy: Genetic testing and platelet function assays can guide individualized treatment.
2. New Antiplatelet Agents: PAR-1 inhibitors (e.g., vorapaxar) and next-generation P2Y12 inhibitors may offer better efficacy with lower bleeding risk.

3. Nanotechnology in Drug Delivery: Targeted delivery of antiplatelet agents could improve effectiveness and reduce systemic side effects.
4. Artificial Intelligence (AI) in Risk Prediction: AI-based models may help predict thrombotic and bleeding risks, improving patient management.

CONCLUSION

Antiplatelet therapy plays a crucial role in the management of coronary heart disease (CHD), significantly reducing the risk of thrombotic events such as myocardial infarction and stent thrombosis. Aspirin and P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) remain the cornerstone of treatment, with dual antiplatelet therapy (DAPT) being the standard approach for patients undergoing percutaneous coronary intervention (PCI) and those with acute coronary syndrome (ACS). Despite its proven benefits, antiplatelet therapy presents several challenges, including variability in patient response, risk of bleeding complications, and uncertainty regarding optimal treatment duration.

High platelet reactivity (HPR) in some patients reduces the efficacy of certain antiplatelet agents, particularly clopidogrel, necessitating genetic testing and platelet function assays for a more personalized approach. Additionally, balancing the benefits of preventing thrombotic events against the increased risk of bleeding remains a clinical dilemma, especially in elderly patients or those requiring long-term therapy. The development of newer antiplatelet agents, such as PAR-1 inhibitors and next-generation P2Y12 inhibitors, aims to address these concerns by offering improved efficacy with a potentially lower risk of bleeding.

Future advancements in precision medicine, including the use of pharmacogenomics, artificial intelligence (AI)-based risk stratification, and nanotechnology-driven drug delivery systems, hold promise for optimizing antiplatelet therapy. These innovations may enable a more individualized approach, minimizing adverse effects while maximizing therapeutic benefits.

In conclusion, while significant progress has been made in antiplatelet therapy, ongoing research and innovation are necessary to overcome existing challenges and further enhance patient outcomes. A personalized approach, integrating genetic testing, risk assessment, and emerging pharmacological advancements, will be key to achieving optimal treatment strategies in CHD patients.

REFERENCES

1. Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., et al. (2007). Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. *Journal of the American College of Cardiology, 49*(14), 1505-1516.
2. Bhatt, D. L., Fox, K. A. A., Hacke, W., et al. (2010). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *New England Journal of Medicine, 363*(10), 930-942.
3. Bonaca, M. P., Bhatt, D. L., Cohen, M., et al. (2015). Long-term use of ticagrelor in patients with prior myocardial infarction. *New England Journal of Medicine, 372*(19), 1791-1800.
4. Cuisset, T., Deharo, P., Quilici, J., et al. (2012). Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC randomized study. *European Heart Journal, 38*(42), 3070-3078.
5. Eikelboom, J. W., Connolly, S. J., Bosch, J., et al. (2017). Rivaroxaban with or without aspirin in stable cardiovascular disease. *New England Journal of Medicine, 377*(14), 1319-1330.
6. Gagne, J. J., Bykov, K., Choudhry, N. K., et al. (2013). Effect of genetic variants on clopidogrel efficacy in patients with cardiovascular disease: A systematic review and meta-analysis. *JAMA, 310*(23), 2609-2617.
7. Levine, G. N., Bates, E. R., Bittl, J. A., et al. (2016). 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. *Circulation, 134*(10), e123-e155.
8. Li, Y., Sperry, J. L., & Moore, E. E. (2018). Antiplatelet therapy in trauma: The role of platelet function testing. *Transfusion Medicine Reviews, 32*(2), 94-101.
9. Mehta, S. R., Yusuf, S., Peters, R. J., et al. (2001). Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention. *The Lancet, 358*(9281), 527-533.
10. Mehran, R., Baber, U., Sharma, S. K., et al. (2019). Ticagrelor with aspirin or alone in high-risk patients after coronary intervention. *New England Journal of Medicine, 381*(21), 2032-2042.
11. Montalescot, G., Wiviott, S. D., Braunwald, E., et al. (2009). Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction. *New England Journal of Medicine, 361*(10), 935-944.
12. Patrono, C., Morais, J., Baigent, C., et al. (2017). Antiplatelet agents for the treatment and prevention of atherothrombosis. *European Heart Journal, 38*(29), 2315-2329.
13. Sabatine, M. S., Cannon, C. P., Gibson, C. M., et al. (2005). Effect of clopidogrel pretreatment

before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. *JAMA, 294*(10), 1224-1232.

14. Sibbing, D., Aradi, D., Alexopoulos, D., et al. (2019). Updated expert consensus on platelet function testing in patients undergoing percutaneous coronary intervention. *European Heart Journal, 40*(3), 263-271.
15. Steg, P. G., Bhatt, D. L., Simon, T., et al. (2019). Ticagrelor in patients with stable coronary disease and diabetes. *New England Journal of Medicine, 381*(14), 1309-1320.

